Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir

- PMLiVE

ViiV boosted by positive phase III results for HIV drug Triumeq

Data reaffirms benefitsof drug in comparison to current antiretroviral medications 

Gilead Sciences

Gilead reports positive data on ‘universal’ hepatitis C regimen

Sets sights on regulatory approval for combination therapy 

- PMLiVE

Gilead and GSK pulmonary hypertension drugs work in tandem

Letairis and Adcirca combined shows clear therapeutic benefit

- PMLiVE

Bionor gears up for ‘kick and kill’ HIV data

Could also be used in conjunction with Celgene's cancer drug Revlimid

Roche Basel Switzerland

Roche and AbbVie’s leukaemia drug set for filing by year-end

Blood cancer treatment venetoclax faces a tough market if approved

- PMLiVE

Humira gains EU licence first for Hidradenitis Suppurativa

Thirteenth licence for the drug in Europe

- PMLiVE

Hints of recovery at GSK as group sales climb

Drug revenue still falling but vaccines and HIV drugs help offset Advair decline

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

- PMLiVE

HIV vaccine from J&J starts human trials

Vaccine provided complete protection in primates for similar infection 

China flag thumb

HIV deal in China helps GSK rebuild tattered reputation

Country to receive discounted supplies of HIV drug Tivicay

Gilead Sciences

Gilead files Complera follow-up with FDA

HIV therapy could be approved in the US by the end of this year

- PMLiVE

BMS drops antiviral research in R&D shake-up

Up to 100 positions set to be lost by the US company’s research shift

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links